![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Alpha Tau Medical Cancer Radiotherapy Gains Breakthrough Device Designation
Alpha Tau Medical Cancer Radiotherapy Gains Breakthrough Device Designation
![Breakthrough Status](https://www.fdanews.com/ext/resources/test/Device_Images6/Breakthrough-Status.gif?t=1620169812&width=430)
June 21, 2021
Israeli company Alpha Tau Medical’s alpha-radiation cancer therapy Alpha DaRT has received a Breakthrough Device designation from the FDA.
Alpha Tau submitted clinical data to the FDA to support the designation, including a pilot study of the treatment for squamous-cell carcinoma (SCC) of the skin, head and neck in which almost 80 percent of the lesions showed a complete response and 100 percent demonstrated a partial or complete response.
The breakthrough designation applies to use of the Jerusalem-based company’s device to treat SCC of the skin and oral cavity without curative standard of care.
Upcoming Events
-
21Oct